ArticlePloS one2026
Lipid droplet associated protein HILPDA promotes hypoxia-induced ferroptosis by driving LPCAT3-mediated polyunsaturated phospholipids enrichment.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Each year, tens of millions of individuals sojourn to high-altitude environments (>2500 m), where they face the significant physiological challenge of hypoxia, a condition that often induces a range of gastrointestinal disorders. While our prior studies linked this damage to ferroptosis, the role of hypoxia-inducible lipid droplet-associated protein (HILPDA), a hypoxia inducible factor-1α/2α (HIF-1α/2α) downstream regulator, in this process remains unclear. This study aimed to explore the role and mechanism of HILPDA in regulating ferroptosis of normal human gastric and small intestinal epithelial cells (NGEC and HIEC) under hypoxic conditions. Our results found that overexpression of HIF-1α, HIF-2α, and HILPDA exacerbated hypoxia-induced cell death, which was reversed by the ferroptosis inhibitor ferrostatin-1. Knockdown of HIF-1α/2α inhibited HILPDA expression. Furthermore, knockdown of HILPDA led to a reduction of the hypoxia-induced lipid peroxidation, and the ferroptotic characteristics of cellular mitochondria observed under transmission electron microscopy. Conversely, HILPDA overexpression reversed the protective effects of HIF-1α/2α knockdown. Lipidomic analysis further revealed that HILPDA knockdown significantly decreased the levels of polyunsaturated fatty acid-phosphatidylcholines (PUFA-PCs) and phosphatidylethanolamines (PEs) under hypoxia. Compared to HIF-1α knockdown, HILPDA knockdown led to a slight difference in PUFA-PEs without significant difference in PCs and phosphatidylinositols (PIs) under hypoxia. Compared to HIF-2α knockdown, HILPDA knockdown resulted in negligible differences in PEs, PCs, and PIs. In addition, HILPDA knockdown downregulated Lysophosphatidylcholine Acyltransferase 3 (LPCAT3), and overexpression of LPCAT3 significantly attenuated the inhibitory effect of HILPDA knockdown on hypoxia-induced ferroptosis. In conclusion, HILPDA enhanced susceptibility to hypoxia-induced ferroptosis in NGEC and HIEC by enriching PUFA-containing phospholipids through LPCAT3. These findings identified the HIF-1α/2α-HILPDA-LPCAT3 axis as a pivotal pathway driving hypoxia-induced ferroptosis, therefore providing potential therapeutic targets for gastric and small intestinal mucosal injury associated with hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.